High dose fish oil lipid emulsion (FOLE) use in pediatric patients: A case series

Read full text Summarise with VIRAT
Authors: Sean Coyne, Uyen Le, Margaret Murphy, Kathleen M. Gura
Cited by: 0
References: 14

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Intestinal Failure-Associated Liver Disease (IFALD) presents significant challenges in pediatric patients on long-term parenteral nutrition (PN). Case report: We conducted a case series to evaluate safety and efficacy of administering higher dose (2 g/kg/day) Omegaven® (Fresenius Kabi AG, Bad Homburg, Germany), a fish oil-based lipid emulsion (FOLE), in pediatric patients with IFALD. Ten patients at Boston Children's Hospital were found to have received FOLE at 2 g/kg/day. Data was retrospectively collected from electronic health records, including demographics, laboratory values, and treatment outcomes. Conclusion: All patients using higher dose FOLE successfully transitioned to 20-hour PN cycles with FOLE 2 g/kg/day, meeting daily caloric requirements and preventing hypoglycemia. No adverse reactions were reported. For most patients, liver function markers remained within normal limits. Our findings suggest higher dose FOLE can facilitate PN cycling and promote growth. Further studies are warranted to validate these findings and establish optimal dosing for this patient population.

Fields of Study & Subjects

Clinical Nutrition and Gastroenterology Central Venous Catheters and Hemodialysis Aquaculture Nutrition and Growth

Publication details

Journal / source
Intestinal failure.
Volume
10
Pages
100367–100367
Publication date
27 March 2026
Language
EN